1 results match your criteria: "Research and Development Clinical Science Division[Affiliation]"
Neuropsychiatr Dis Treat
April 2021
Research and Development Clinical Science Division, Janssen Pharmaceutical K.K., Tokyo, Japan.
Purpose: The aim of this study was to clarify whether early symptomatic improvement in response to a long-acting injectable antipsychotic (LAI) contributes to subsequent social functional remission in patients with schizophrenia using the previous clinical trial data (EudraCT registration number: 2011-004889-15). Associations between other factors and social functional remission were also explored.
Patients And Methods: We analyzed 428 patients with schizophrenia in which the personal and social performance scale (PSP) and the involvement evaluation questionnaire (IEQ) at the time of the base line were recorded.
© LitMetric 2025. All rights reserved.